212 related articles for article (PubMed ID: 35326641)
1. Pharmacologic Strategies for Post-Transplant Maintenance in Acute Myeloid Leukemia: It Is Time to Consider!
Abou Dalle I; El Cheikh J; Bazarbachi A
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326641
[TBL] [Abstract][Full Text] [Related]
2. Innovations in conditioning and post-transplant maintenance in AML: genomically informed revelations on the graft-versus-leukemia effect.
Murdock HM; Ho VT; Garcia JS
Front Immunol; 2024; 15():1359113. PubMed ID: 38571944
[TBL] [Abstract][Full Text] [Related]
3. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
4. Post-transplant maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation harmonizing multiple therapeutic modalities including targeted therapy, immunotherapy and cellular therapy.
Al-Shaibani E; Novitzky-Basso I; Mattsson J; Kim DDH
Int J Hematol; 2023 Jul; 118(1):1-17. PubMed ID: 37212948
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of a Second Allogeneic Hematopoietic Cell Transplant in Relapsed Acute Myeloid Leukemia: Results of a Systematic Review and Meta-Analysis.
Kharfan-Dabaja MA; Reljic T; Yassine F; Nishihori T; Kumar A; Tawk MM; Keller K; Ayala E; Savani B; Mohty M; Aljurf M; Saber W
Transplant Cell Ther; 2022 Nov; 28(11):767.e1-767.e11. PubMed ID: 35970301
[TBL] [Abstract][Full Text] [Related]
6. Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia.
Candoni A; De Marchi F; Zanini F; Zannier ME; Simeone E; Toffoletti E; Chiarvesio A; Cerno M; Filì C; Patriarca F; Fanin R
Exp Hematol; 2017 May; 49():25-33. PubMed ID: 28159598
[TBL] [Abstract][Full Text] [Related]
7. Relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia: an overview of prevention and treatment.
Kreidieh F; Abou Dalle I; Moukalled N; El-Cheikh J; Brissot E; Mohty M; Bazarbachi A
Int J Hematol; 2022 Sep; 116(3):330-340. PubMed ID: 35841458
[TBL] [Abstract][Full Text] [Related]
8. Case Report: Preemptive Treatment With Low-Dose PD-1 Blockade and Azacitidine for Molecular Relapsed Acute Myeloid Leukemia With RUNX1-RUNX1T1 After Allogeneic Hematopoietic Stem Cell Transplantation.
Tang Y; Zhou Z; Yan H; You Y
Front Immunol; 2022; 13():810284. PubMed ID: 35185899
[TBL] [Abstract][Full Text] [Related]
9. Application of prophylactic or pre-emptive therapy after allogeneic transplantation for high-risk patients with t(8;21) acute myeloid leukemia.
Guo W; Liu X; Wang M; Liu J; Cao Y; Zheng Y; Zhai W; Chen X; Zhang R; Ma Q; Yang D; Wei J; He Y; Pang A; Feng S; Han M; Jiang E
Hematology; 2023 Dec; 28(1):2205739. PubMed ID: 37104677
[TBL] [Abstract][Full Text] [Related]
10. Pharmacologic Therapies to Prevent Relapse of Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation.
Antar AI; Otrock ZK; Abou Dalle I; El-Cheikh J; Bazarbachi A
Front Oncol; 2020; 10():596134. PubMed ID: 33224890
[TBL] [Abstract][Full Text] [Related]
11. Treatment of AML Relapse After Allo-HCT.
Webster JA; Luznik L; Gojo I
Front Oncol; 2021; 11():812207. PubMed ID: 34976845
[TBL] [Abstract][Full Text] [Related]
12. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.
Gilleece MH; Labopin M; Yakoub-Agha I; Volin L; Socié G; Ljungman P; Huynh A; Deconinck E; Wu D; Bourhis JH; Cahn JY; Polge E; Mohty M; Savani BN; Nagler A
Am J Hematol; 2018 Sep; 93(9):1142-1152. PubMed ID: 29981272
[TBL] [Abstract][Full Text] [Related]
13. Post-transplant cyclophosphamide and early mixed donor Chimerism in myeloid malignancies; a single-center experience.
Hoff FW; Chung SS; Patel PA; Premnath N; Khatib J; Tadic-Ovcina M; AhmedRabie A; Helton D; Yohannes S; Shahan J; Patel H; Geethakumari PR; Vusirikala M; Collins RH; Madanat YF
Transpl Immunol; 2023 Apr; 77():101808. PubMed ID: 36842566
[TBL] [Abstract][Full Text] [Related]
14. Peripheral Blood CD34 Donor Chimerism has Greater Clinical Utility Than CD3 for Detecting Relapse after Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic Syndrome.
Das TP; North D; Fleming SA; Tan JLC; Ivey A; Cummings NJ; Spencer A; Patil SS; Widjaja JML; Swain MI; Bourke C; O'Brien ME; Kliman DS; Curtis DJ
Transplant Cell Ther; 2023 Jul; 29(7):454.e1-454.e8. PubMed ID: 36966870
[TBL] [Abstract][Full Text] [Related]
15. Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT.
Tsirigotis P; Byrne M; Schmid C; Baron F; Ciceri F; Esteve J; Gorin NC; Giebel S; Mohty M; Savani BN; Nagler A
Bone Marrow Transplant; 2016 Nov; 51(11):1431-1438. PubMed ID: 27295272
[TBL] [Abstract][Full Text] [Related]
16. Overcoming relapse: prophylactic or pre-emptive use of azacitidine or FLT3 inhibitors after allogeneic transplantation for AML or MDS.
Najima Y
Int J Hematol; 2023 Aug; 118(2):169-182. PubMed ID: 37036626
[TBL] [Abstract][Full Text] [Related]
17. Repetitively Administered Low-Dose Donor Lymphocyte Infusion for Prevention of Relapse after Allogeneic Stem Cell Transplantation in Patients with High-Risk Acute Leukemia.
Tsirigotis P; Gkirkas K; Kitsiou V; Chondropoulos S; Athanassiades T; Thomopoulos T; Tsirogianni A; Stamouli M; Karagiannidi A; Siafakas N; Pappa V; Nagler A
Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34070786
[TBL] [Abstract][Full Text] [Related]
18. Maintenance therapy for AML after allogeneic HCT.
Nayak RK; Chen YB
Front Oncol; 2022; 12():895771. PubMed ID: 36016625
[TBL] [Abstract][Full Text] [Related]
19. The Elephant in The Room: AML Relapse Post Allogeneic Hematopoietic Cell Transplantation.
Abou Dalle I; Atoui A; Bazarbachi A
Front Oncol; 2021; 11():793274. PubMed ID: 35047405
[TBL] [Abstract][Full Text] [Related]
20. Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.
Gyurkocza B; Gutman J; Nemecek ER; Bar M; Milano F; Ramakrishnan A; Scott B; Fang M; Wood B; Pagel JM; Baumgart J; Delaney C; Maziarz RT; Sandmaier BM; Estey EH; Appelbaum FR; Storer BE; Deeg HJ
Biol Blood Marrow Transplant; 2014 Apr; 20(4):549-55. PubMed ID: 24440648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
